---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-083410"
form_type: "8-K"
ticker: "MRK"
cik: "0000310158"
company_name: "Merck & Co., Inc."
filed_at: "2022-07-28T23:59:59+00:00"
generated_at: "2026-06-24T07:43:28.811615+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Merck Q2 revenue up 28% to $14.6B; non-GAAP EPS $1.87 vs $0.61; raises 2022 sales guidance

## Summary
- KEYTRUDA sales rose 26% to $5.3B; GARDASIL/GARDASIL 9 up 36% to $1.7B, driven by China demand.
- LAGEVRIO contributed $1.2B in Q2 sales; full-year outlook maintained at $5.0-$5.5B.
- GAAP EPS $1.55 vs $0.48; non-GAAP EPS $1.87 vs $0.61, reflecting strong operational performance.
- Company raised and narrowed 2022 full-year sales guidance to $57.5-$58.5B (18-20% growth).
- Non-GAAP EPS guidance narrowed to $7.25-$7.35; includes ~$0.09 impact from Orion upfront payment.

## SEC filing metadata
- accession: 0001104659-22-083410
- form_type: 8-K
- ticker: MRK
- cik: 0000310158
- company_name: Merck & Co., Inc.
- filed_at: 2022-07-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/310158/000110465922083410/0001104659-22-083410-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/310158/000110465922083410/tm2221828d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-083410
- JSON: https://secwatch.observer/filing/0001104659-22-083410.json
- Plain text: https://secwatch.observer/filing/0001104659-22-083410.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.